Abstract: Provided herein is Compound I or a pharmaceutically acceptable salt thereof for use in the prevention and/or treatment of a kidney condition or disease in a subject exposed to a nephrotoxin capable of inducing said kidney condition or disease.

Abstract: A method of assessing damage to a composite member requires the formation of a composite member comprising at least one cavity. A first pressure differential is then established between the cavity and the surrounding ambient pressure. The rate of change of the pressure differential over a first predetermined period is monitored and then the pressure differential is allowed to subside. The result of the monitoring step is stored as a reference value, so that after the composite member is damaged, or after it has been in service for a predetermined time, the test can be repeated and compared with the reference value. If the result of the repeated monitoring differs from the reference value by more than a predetermined amount, it is determined that the composite member is defective.

Abstract: The present invention provides a cyclosporin analog and use thereof, and in particular relates to a compound and use thereof as a mitochondrial protective agent for storing a donated organ. The compound is a compound of formula 1 or a salt thereof, wherein n is 2-5, and R1 and R2 are independently selected from H or C1-C4 alkyl, wherein R1 and R2 can be linked together to form a C3-C5 heteroalkyl ring.

Abstract: A method of assessing damage to a composite member requires the formation of a composite member comprising at least one cavity. A first pressure differential is then established between the cavity and the surrounding ambient pressure. The rate of change of the pressure differential over a first predetermined period is monitored and then the pressure differential is allowed to subside. The result of the monitoring step is stored as a reference value, so that after the composite member is damaged, or after it has been in service for a predetermined time, the test can be repeated and compared with the reference value. If the result of the repeated monitoring differs from the reference value by more than a predetermined amount, it is determined that the composite member is defective.

Abstract: A handling strut connects the powertrain of an automobile to a structural member, such as a panel in the engine bay. The handling strut is comprised of two strut members, one connected to the powertrain, the other connected to the structural member. A shaft attached to one strut member, extends through a bushing provided in the other strut member and an air gap is provided between the bushing and the shaft, such that when the engine is idle, or not accelerating, and in the absence of hard cornering, the strut members are decoupled. The isolation of the strut members when not required to control engine roll, reduces/avoids transmission of noise, vibration and/or harshness.

Abstract: A handling strut connects the powertrain of an automobile to a structural member, such as a panel in the engine bay. The handling strut is comprised of two strut members, one connected to the powertrain, the other connected to the structural member. A shaft attached to one strut member, extends through a bushing provided in the other strut member and an air gap is provided between the bushing and the shaft, such that when the engine is idle, or not accelerating, and in the absence of hard cornering, the strut members are decoupled. The isolation of the strut members when not required to control engine roll, reduces/avoids transmission of noise, vibration and/or harshness.

Abstract: Disclosed are cyclosporine derivatives in which the 3-Sarcosine carbon and 5-Valine nitrogen are each substituted by a non-hydrogen substituent, and their use as pharmaceuticals, in particular for the treatment of hepatitis C virus.

Abstract: Cyclosporin derivatives, methods of manufacturing the cyclosporin derivatives and methods for treating subjects infected with certain viruses, including hepatitis virus or HIV by administering the cyclosporin derivatives are described.

Abstract: Cyclosporin derivatives, methods of manufacturing the cyclosporin derivatives and methods for treating subjects infected with certain viruses, including hepatitis virus or HIV by administering the cyclosporin derivatives are described.

Abstract: Disclosed herein are compounds of general formula (I): wherein A, B, R1 and R2 are as defined in the specification, and their use as pharmaceuticals.

Abstract: Compounds are disclosed of general formula (I): wherein A, B, R1 and R2 are as defined in the description, and their use as pharmaceuticals.

Abstract: Disclosed herein are compounds of general formula (I): wherein A, B, R1 and R2 are as defined in the specification, and their use as pharmaceuticals.

Abstract: Disclosed are cyclosporine derivatives in which the 3-Sarcosine carbon and 5-Valine nitrogen are each substituted by a non-hydrogen substituent, and their use as pharmaceuticals, in particular for the treatment of hepatitis C virus.

Abstract: Compounds are disclosed of general formula (I): wherein A, B and R1 are as defined in the description, and their use as pharmaceuticals.

Abstract: This invention relates to a compound of general formula (I): wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors, for use in treatment of hepatitis C virus.

Abstract: Fused pyradazine derivatives which are usefule as CDK inhibitors are described herein. The described invention alos includes methods of making such fused pyradazine derivatives as wells as methods of using the same in the treatment of hyperproliferative diseases.

Abstract: Oxazole derivatives, which are useful as VEGFR2, CDK2, and CDK4 inhibitors are described herein. The described invention also includes methods of making such oxazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Abstract: Compounds of Formula (I): salts or solvates or physiologically functional derivatives thereof, wherein Z is CH or N, and R1, R2, and R4 are various substituent groups, are protein kinase inhibitors

Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.